arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Verastem, Inc.

VSTM
$9.38 ▼ -0.49 (-4.96%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Verastem, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF Margin (%). These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $650.1M
Dividend Yield —
Revenue Growth 209.1%
Op. Margin None
ROIC -235.0% ↗
FCF / Share $-1.98 ↗
Trailing P/E —
Price / Book 12.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$30.91M
↑ +209.1% —
Net Income Profit after all expenses
$-209.47M
↓ -60.3% —
Operating Margin Operating profit as % of sales
-55.8%
↑ +84.3% —
FCF / Share Free cash flow per share
$-1.98
↑ +32.4% —
Long-Term Debt Long-term obligations
$40.72M
↑ +1.6% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -235.0% is weak on an absolute basis (target > 10%)
  • FCF Margin (%)FCF Margin (%) of -444.8% is weak on an absolute basis (target > 10%)
  • Interest CoverageInterest Coverage of -149.50x is weak on an absolute basis (target > 5x)
  • FCF / Net IncomeFCF / Net Income of 0.66x is weak on an absolute basis (target > 1x)

Health Breakdown

Profitability ↓
18
Financial Health ↓
18
Cash Quality ↓
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 63 quarters